CHI Drug Discovery Chemistry, San Diego 8-12th April
Targeting Deubiquitylases (DUBs): Opportunities for Collaborative Drug Discovery
Ubiquigent’s Scientific and Business Development Director, Dr Jason Brown, will be presenting at the CHI Drug Discovery Chemistry conference in San Diego on Thursday 11th April 2019 at 11:45am.
We will discuss Ubiquigent’s deubiquitylase (DUB) enzyme targeting small molecule hit-to-lead platform featuring: Our in-house DUB-targeting computational and medicinal chemistry capability and a comprehensive small molecule assay workflow featuring our widely accessed DUBprofiler™ and REDOXprofiler™ service platforms.The company also has significant capabilities to target other ubiquitin system proteins – including E3 ligases – and is developing a platform to provide PROTAC hit-to-lead SAR support. Commercial access models: Ubiquigent is providing access to its comprehensive capabilities to execute early stage hit-to-lead projects via our Collaborative Drug Discovery programme. Individual services may also be accessed via Fee For Service (FFS) or FTE routes.
If you’d like to discuss how Ubiquigent enables and supports protein degradation focused drug discovery via modulation and exploitation of the ubiquitin system, we would be pleased to meet you at the conference or contact us directly.
Further information on the conference can be found here.